FIELD: medicine, pharmaceutics.
SUBSTANCE: there are presented: using a compound of formula (1) or its salt for preparing a drug for increasing HIF-1α stabilisation in a cell, as well as for preparing a drug enhancing the immune response in an individual, for preventive management of a wound to avoid an infection, for treatment of the microbial infection, for improvement of efficacy of a vaccine for management of the wound in the individual. What is presented is a pharmaceutical composition containing the above HIF-1α prolyl hydroxylase inhibitor and one or more additives. What is shown is achieving the declared applications by using the new compound of formula 
(1) with the HIF-1α prolyl hydroxylase (HIFPH2 (EGLN1)) inhibitor. It makes it applicable for treating HIF-1 alpha activity related diseases, conditions and/or syndromes.
EFFECT: preparing the drug for increasing HIF-1α stabilisation in a cell.
26 cl, 20 dwg, 8 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF TREATING COLITIS | 2010 |
|
RU2518416C2 |
| PROLYL HYDROXYLASE INHIBITORS AND APPLICATION METHODS THEREOF | 2007 |
|
RU2429226C9 |
| PROLYL HYDROXYLASE INHIBITORS | 2010 |
|
RU2518071C2 |
| METHOD FOR PRODUCING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANE ACIDS, ESTERS AND AMIDES | 2012 |
|
RU2764667C2 |
| METHOD OF PRODUCING [(3-HYDROXYPYRIDINE-2-CARBONYL)AMINO]ALKANOIC ACIDS, ESTERS AND AMIDES | 2012 |
|
RU2602083C2 |
| METHOD OF TREATING VASCULAR LEAK SYNDROME | 2010 |
|
RU2539917C2 |
| APPLICATION OF STABILISERS OF HIF- ALPHA FOR INTENSIFICATION OF ERYTHROPOIESIS | 2004 |
|
RU2414214C2 |
| TRICYCLIC JANUS KINASE 1 INHIBITORS, COMPOSITIONS, METHODS OF PRODUCTION AND USE THEREOF | 2019 |
|
RU2824349C2 |
| TRIAZOLOPYRIDINE COMPOUND AND ACTION THEREOF AS PROLYL HYDROXYLASE INHIBITOR AND ERYTHROPOIETIN PRODUCTION INDUCER | 2010 |
|
RU2538963C2 |
| NEUROACTIVE STEROIDS, COMPOSITIONS AND USE THEREOF | 2014 |
|
RU2696585C2 |
